A new trading day began on Friday, with PDS Biotechnology Corporation (NASDAQ: PDSB) stock price down -9.51% from the previous day of trading, before settling in for the closing price of $1.05. PDSB’s price has ranged from $1.05 to $4.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 7.77%. With a float of $43.68 million, this company’s outstanding shares have now reached $45.40 million.
In an organization with 24 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
PDS Biotechnology Corporation (PDSB) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of PDS Biotechnology Corporation is 3.78%, while institutional ownership is 9.35%. The most recent insider transaction that took place on Feb 28 ’25, was worth 25,000. In this transaction Director of this company bought 15,060 shares at a rate of $1.66, taking the stock ownership to the 61,213 shares. Before that another transaction happened on Feb 28 ’25, when Company’s Director bought 15,061 for $1.66, making the entire transaction worth $25,001. This insider now owns 78,851 shares in total.
PDS Biotechnology Corporation (PDSB) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.82% during the next five years compared to 6.42% growth over the previous five years of trading.
PDS Biotechnology Corporation (NASDAQ: PDSB) Trading Performance Indicators
Here are PDS Biotechnology Corporation’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.03, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of PDS Biotechnology Corporation (PDSB)
Let’s dig in a bit further. During the last 5-days, its volume was 0.37 million. That was inferior than the volume of 0.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.05%. Additionally, its Average True Range was 0.13.
During the past 100 days, PDS Biotechnology Corporation’s (PDSB) raw stochastic average was set at 1.59%, which indicates a significant decrease from 7.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.86% in the past 14 days, which was lower than the 97.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3570, while its 200-day Moving Average is $2.4767. However, in the short run, PDS Biotechnology Corporation’s stock first resistance to watch stands at $1.0099. Second resistance stands at $1.0698. The third major resistance level sits at $1.1195. If the price goes on to break the first support level at $0.9003, it is likely to go to the next support level at $0.8506. Assuming the price breaks the second support level, the third support level stands at $0.7907.
PDS Biotechnology Corporation (NASDAQ: PDSB) Key Stats
With a market capitalization of 43.13 million, the company has a total of 45,396K Shares Outstanding. Currently, annual sales are 0 K while annual income is -37,610 K. The company’s previous quarter sales were 0 K while its latest quarter income was -7,950 K.
